S
Samil Pharmaceutical Co Ltd
KRX:000520
Samil Pharmaceutical Co Ltd
KRX:000520
Price:
10 050
KRW
1.72%
Market Closed
Market Cap:
₩218B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Samil Pharmaceutical Co Ltd
KRX:000520
|
KR |
|
White Organic Retail Ltd
BSE:542667
|
IN |
Relative Value
The Relative Value of one Samil Pharmaceutical Co Ltd stock under the Base Case scenario is 12 741 KRW. Compared to the current market price of 10 050 KRW, Samil Pharmaceutical Co Ltd is Undervalued by 21%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
12 741
KRW
Undervaluation 21%
S
Multiples Across Competitors
Competitors Multiples
Samil Pharmaceutical Co Ltd Competitors
Samil Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
S
|
Samil Pharmaceutical Co Ltd
KRX:000520
|
213.4B KRW | 1 | -7.9 | -85.1 | -20.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.4 | 42.3 | 28.5 | 30.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.6 | 11.1 | 12.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.5B GBP | 4.9 | 28.2 | 15.7 | 22.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 5.1 | 20.6 | 12.8 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
